LILRB4 and acute myeloid leukemia: Preclinical evaluation of an anti-ILT3 CAR T-cell model has demonstrated efficient effector function in vitro and in vivo against ILT3+ AML cells (MV4-11, PriAML-1, THP-1, PriAML-2, MOLM13, PriMonoctye) with an E:T ratio of 5:1 resulting in between approximately 50% to 90% specific cell lysis compared to only approximately 20% specific cell lysis in non-transduced control T-cells after 4 hours.